MyPsoriasisTeam

Deucravacitinib, sold under the brand name Sotyktu, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It is a tyrosine kinase 2 (TYK2) inhibitor that works by decreasing the Show Full Answer

Deucravacitinib, sold under the brand name Sotyktu, is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It is a tyrosine kinase 2 (TYK2) inhibitor that works by decreasing the amount of certain molecules that cause inflammation. This helps reduce psoriasis severity, skin coverage, and symptoms like pain, burning, skin tightness, itching, and stinging.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Sotyktu (Deucravacitinib) for Psoriasis | MyPsoriasisTeam

FDA Approves New Oral Drug Sotyktu for Adults With Plaque Psoriasis | MyPsoriasisTeam